Introduction
Anaerobes are established causes of serious human infections, especially in debilitated hosts. Although infections caused by members of the Bacteroides fragilis group occur most commonly, infections caused by other Gram-negative anaerobic bacilli, as well as by Gram-positive cocci and clostridia, are increasingly encountered. The susceptibility spectrum of clinically isolated anaerobes is changing: Although -lactamase production, and concomitant resistance to -lactams, is the rule in the B. fragilis group, both phenomena are increasingly encountered in non-B. fragilis group Bacteroides, Prevotella, Porphyromonas and Fusobacterium spp. -Lactamase production has also been described in some non-Clostridium perfringens species of clostridia. Metronidazole resistance, apart from being the rule among anaerobic Gram-positive non-spore-forming bacilli (which most often prove to be microaerophiles), has been reported in peptostreptococci, non-C. perfringens clostridia and members of the B. fragilis group. Additionally, clindamycin resistance is not unusual among anaerobic Gram-negative bacilli. 1 Commercially available quinolones such as ciprofloxacin, ofloxacin, fleroxacin, pefloxacin, enoxacin, lomefloxacin, sparfloxacin and grepafloxacin, are inactive or marginally active against anaerobes, with MICs either higher than, or clustering around, breakpoints. [2] [3] [4] Trovafloxacin is a new quinolone with a broad spectrum of activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. 
Materials and methods

Bacteria and antimicrobials
All anaerobic strains were recent clinical isolates (1994) (1995) (1996) (1997) 
MIC and chequerboard titration assays
MIC and chequerboard titration assays were performed 13 on 156 strains (Table I) USA) and 13 mm Teflon-faced rubber septa (Fisher Scientific, Inc., Pittsburgh, PA, USA). A 100 L aliquot was then delivered by syringe into a similar tube containing 5 mL prereduced Brucella broth. All inocula were prepared in the glove box. Tubes were then removed from the glove box and incubated in a shaking water bath at 35°C for 24 h. Viability counts were then done in the glove box to obtain similar starting inocula (see below).
Time-kill determinations
Empty tubes (as above) were then filled on the bench top by syringe with 2.7 mL prereduced Brucella broth with additives (5% lysed horse blood, 5 mg/L haemin, 1 mg/L vitamin K), 1 mL antibiotic dilutions (each drug tested alone, and trovafloxacin in combination with clindamycin or metronidazole) prepared in Brucella broth, 200 L Oxyrase solution (Oxyrase Inc., Mansfield, OH, USA) and 100 L inoculum (as above), after carefully expelling all air from all syringes. Controls without antibiotic were included in each run. Initial inocula were 1-5 ϫ 10 6 cfu/mL (confirmed by prior viability counts). 3, 4 For each of the three drugs tested alone, the MIC and concentrations one dilution above and three dilutions below the MIC were tested. Combinations were tested at the MIC and one or two dilutions below the MIC of each drug. Viability counts were performed after incubation at 35°C in a shaking water bath at 0, 6, 12, 24 and 48 h by incubating plates inside the glove box at 35°C for 48 h. Drug carryover was addressed by dilution, as described previously.
3,4 Synergy 13 was defined as a у2 log 10 decrease in cfu/mL between the combination and its most active constituent after 48 h 3, 4 and the number of surviving organisms in the presence of the combination was у2 log 10 cfu/mL below the starting inoculum. Time-kills yielded additive results when the number of surviving organisms in the combination was 0-1.9 log 10 cfu/mL below the starting inoculum 3,4,13 Synergy time-kill tests were done in duplicate and yielded identical results. Atmosphere inside the glove box for all tests consisted of 85% N 2 , 10% CO 2 and 10% H 2 .
Results
Results of MIC studies are presented in Table I . MIC 50 / MIC 90 values (mg/L) of each drug alone against all 156 strains were: trovafloxacin, 0.5/1; clindamycin, 0.25/2; metronidazole, 1/2. Chequerboard testing (Table II) showed that synergic FIC indices of р0.5 were seen in two B. fragilis group strains with trovafloxacin-clindamycin and in seven strains (five B. fragilis and two fusobacteria) with trovafloxacin-metronidazole. All other combinations were additive (FIC indices Ͼ0.5-2.0, with none Ͼ2.0); no antagonistic FICs Ͼ4.0 were seen.
Because chequerboard assays are less discriminatory than time-kill tests in determining synergy, and because previous studies using aerobic organisms have shown that all strains shown to be synergic by chequerboard methods were also synergic as judged by time-kill (but not vice versa), [14] [15] [16] [17] [18] we elected to screen all 156 strains by chequerboard methods, and then test 12 representative strains which had additive FIC indices by time-kill. Strains chosen for time-kill synergy assays were selected to represent a spectrum of clinically significant anaerobe species. Table III presents results of time-kill experiments. All combinations yielded additive FICs with the chequerboard method. Results indicated that synergy (у2 log 10 decrease in cfu/mL at 48 h compared with the more active drug alone) was found between trovafloxacin at or below the MIC and both clindamycin and metronidazole at or below the MIC in one strain each of B. fragilis, B. thetaiotaomicron, Prevotella intermedia, Fusobacterium varium, Peptostreptococcus asaccharolyticus and Clostridium bifermentans. Synergy between trovafloxacin (рMIC) and metronidazole alone was seen in one strain each of Bacteroides distasonis, Prevotella bivia, Fusobacterium mortiferum, P. asaccharolyticus and C. bifermentans. In many cases of synergy, including those at the trovafloxacin MIC, regrowth after 48 h, which was commonly seen with Additivity was defined as a decrease of 0-1.9 log 10 cfu/mL compared with the more active agent alone at 48 h. MICs in parentheses indicate the lowest concentration (mg/L) of each compound that yielded у2 log 10 cfu/mL decrease compared with the more active agent alone at 48 h.
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trovafloxacin alone, was inhibited, and 99.9% killing was observed with the combination after 48 h, but not with trovafloxacin alone. No strains gave synergy between trovafloxacin and clindamycin without giving synergy between trovafloxacin and metronidazole. Lower rates of synergy were found at earlier time periods (data not shown). No attempt was made to subculture clones from regrowth after 48 h with trovafloxacin alone, in order to determine whether resistant mutants were being selected.
Discussion
The anti-anaerobic activity of trovafloxacin has been well established, both by us and by other workers. 2, 11 However, MICs vary between studies; some differences may be ascribed to differences in techniques. 2, 11, 19, 20 Activity of trovafloxacin at a recently established susceptibility breakpoint of 2.0 mg/L 21 is not universal. 2, 11, 19, 20 It has also been established that trovafloxacin is bactericidal at the MIC after 48 h. 3 Studies by us and other workers have established that time-kill testing (which detects bactericidal activity) is more discriminatory than the chequerboard method (which only detects bacteriostatic activity) for synergy testing of a wide variety of Gram-positive and Gram-negative aerobic bacteria, including pneumococci and Gram-negative non-fermenters. [14] [15] [16] [17] [18] The current study detected the same phenomenon for anaerobes, where negligible synergy (but no antagonism) was found with the chequerboard method, while significant synergy, reproducible by duplicate testing, was found in the small number of anaerobes tested by time-kill.
The NCCLS 21 has established trovafloxacin anaerobe breakpoints of р2.0 mg/L (susceptible), 4.0 mg/L (intermediate) and у8.0 mg/L (resistant). Although trovafloxacin is active against most anaerobes at р2.0 mg/L, MICs of some strains cluster around the susceptible breakpoint. Results of this study, which require confirmation by testing of larger numbers of strains, indicate that combination of trovafloxacin with clindamycin or metronidazole yields trovafloxacin MICs which are well below the susceptible breakpoint. Additionally, regrowth with trovafloxacin alone which was sometimes seen after 48 h did not occur in synergic combinations. Further testing of clones which regrew after 48 h with trovafloxacin alone, as well as clinical studies will also be necessary to validate the significance of these in vitro findings.
